EntryPoint Capital »

Lexeo Therapeutics shares owned by EntryPoint Capital

Quarter-by-quarter ownership of Lexeo Therapeutics (LXEO) shares owned by EntryPoint Capital from 13F filings

Historical chart of EntryPoint Capital investment in Lexeo Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Lexeo Therapeutics held by EntryPoint Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lexeo Therapeutics by EntryPoint Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $95k 17k 5.74

More positions owned by EntryPoint Capital

Dolby Laboratories Com Cl A (DLB)
Schrodinger (SDGR)
Roper Industries (ROP)
Acuren Corporation (TIC)
Helios Technologies (HLIO)
News Corp Cl A (NWSA)
HEICO Corporation (HEI)
TJX Companies (TJX)
Bank of America Corporation (BAC)
CenterPoint Energy (CNP)
Harley-Davidson (HOG)
Jefferies Finl Group (JEF)
Knowles (KN)
Cadence Design Systems (CDNS)
Waste Connections (WCN)

View all positions for EntryPoint Capital

Top funds holding Lexeo Therapeutics

Paradigm Biocapital Advisors
BlackRock
Affinity Asset Advisors
RA Capital Management
Henderson Group
Vestal Point Capital
Frazier Life Sciences Management
Citadel Advisors
OrbiMed Advisors
State Street Corporation
Vanguard Capital Management
Woodline Partners
Goldman Sachs Group
venBio Select Advisor
Point72 Asset Management

View all funds holding Lexeo Therapeutics